April 23, 2020 / 1:27 PM / a month ago

BRIEF-Prothera Biologics And Takeda Enter Global Licensing Agreement To Develop Novel Plasma-Derived Therapy Based On Inter-Alpha Inhibitor Proteins

April 23 (Reuters) - Takeda Pharmaceutical Co Ltd:

* PROTHERA BIOLOGICS AND TAKEDA ENTER GLOBAL LICENSING AGREEMENT TO DEVELOP NOVEL PLASMA-DERIVED THERAPY BASED ON INTER-ALPHA INHIBITOR PROTEINS (IAIP)

* TAKEDA - ENTERED LICENSING AGREEMENT WITH PROTHERA TO DEVELOP A NOVEL PLASMA-DERIVED IAIP THERAPY FOR TREATMENT OF ACUTE INFLAMMATORY CONDITIONS

* TAKEDA PHARMACEUTICAL CO LTD - FINANCIAL TERMS OF LICENSING AGREEMENT ARE NOT BEING DISCLOSED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below